¹ World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: World Health Organization, 2003.

² Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. AIDS 2003;34:S521–33.

³ Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30.

⁴ Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15;2109–17.

⁵ Duong M, Piroth L, Peytavin G, et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis 2001;33:386–92.

⁶ Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357–66.

⁷ Romano L, Venturi G, Vivarelli A, et al. Detection of a drug-resistant human immunodeficiency virus variant in a newly infected heterosexual couple. Clin Infect Dis 2002;34:116–7.

⁸ Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377–81.

⁹ World Health Organization. Draf guidelines for surveillance of HIV drug resistance. Geneva: World Health Organization, 2003. (Accessed July 4, 2006 at: http://www.who.int/3by5/publications/documents/ hivdrugsurveillance/en/.)

¹⁰ Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003;17:1741–51.

¹¹ Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002;31:S118–22.

¹² Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antiv Ther 2002;7:185–93.

¹³ Relucio K, Holodniy M. HIV-1 RNA and viral load. Clin Lab Med 2002;22:593–610.

¹⁴ Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis 2003;37:S13–24.

¹⁵ Vergu E, Mallet A, Golmard JL. Available clinical markers of treatment outcome integrated in mathematical models to guide therapy in HIV infection. J Antimicrob Chemother 2004;53:140–3.

¹⁶ Hirsch MS, Brun-Vezinet F, D’Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417–26.

¹⁷ World Health Organization, Joint United Nations Program on HIV/ AIDS, United Nations Children’s Fund. Joint WHO/UNAIDS/ UNICEF statement on use of cotrimoxazole as prophylaxis in HIV exposed and HIV infected children. Geneva: World Health Organization, 2004. (Accessed July 4, 2006 at: http://www.who.int/3by5/mediacentre/en/Cotrimstatement.pdf.)

¹⁸ Villamor E, Fawzi WW. Vitamin A supplementation: implications for morbidity and mortality in children. J Infect Dis 2000;182:S122–33.

¹⁹ Villamor E, Mbise R, Spiegelman D, et al. Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal disease on child growth. Pediatrics 2002;109:E6.

²⁰ Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MWWR 2001;50:1.

²¹ Mofenson LM, Harris DR, Moye J, et al. NICHD IVIG Clinical Trial Study Group. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1 infected children in resource-poor settings. Lancet 2003;362:1625–7.

²² Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004;170:229–38.

²³ Heath KV, Montaner JS, Bondy G, et al. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr Drug Targets 2003;4:13–22.

²⁴ Lenert LA, Feddersen M, Sturley A, et al. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002;113:229–32.

²⁵ Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423–30.

²⁶ Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT cohort, Thailand, 1996–2001. AIDS 2003;17:2191–9.

²⁷ Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38:S90–7.

²⁸ De Maat MM, ter Heine R, van Gorp EC, et al. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003;17:2209–14.

²⁹ Dieterich D. Managing antiretroviral-associated liver disease. J Acquir Immune Defic Syndr 2003;34:S34–9.

³⁰ Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003;5:36–43.

³¹ De Maat MM, ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003;59:457–62.

³² Metry DW, Lahart CJ, Farmer KL, et al. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001;44:S354–7.

³³ Anton P, Soriano V, Jimenez-Nacher I, et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS 1999;13:524–5.

³⁴ Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502–14.

³⁵ Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002;24:565–73.

³⁶ Anonymous. Abacavir hypersensitivity reaction. AIDS Patient Care STDs 2002;16:242.

³⁷ Yamamoto Y, Yasuoka A, Yasuoka C, et al. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection. Jpn J Infect Dis 2000;53:244–5.

³⁸ Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7.

³⁹ Balt CA, Nixon H. Complications of HIV: lipodystrophy, anemia, renal, cardiovascular, and bone diseases. Nurse Pract Forum 2001;12:199–213.

⁴⁰ Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930–3.

⁴¹ Gonzalez A, Everall IP. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs. AIDS 1998;12:2365–7.

⁴² Simpson DM. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002;8:S33–41.

⁴³ Dalakas MC. Peripheral neuropathy and antiretroviral drugs. J Periph Nerv Syst 2001;6:14–20.

⁴⁴ Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol 2003;16:403–9.

⁴⁵ Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001;12:555–62.

⁴⁶ Authier FJ, Chariot P, Gherardi R. Muscular complications in HIV infection. Arch Anat Cytol Pathol 1997;45:174–8.

⁴⁷ Walsh K, Kaye K, Demaerschalk B, et al. AZT myopathy and HIV–1 polymyositis: one disease or two? Can J Neurol Sci 2002;29:390–3.

⁴⁸ Brodie SB, Keller MJ, Ewenstein BM, et al. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998;12:2433–7.

⁴⁹ Hermieu JF, Prevot MH, Ravery V, et al. Nephritic colic due to indinavir. Presse Med 1998;27:465–7.

⁵⁰ Schwartz BF, Schenkman N, Armenakas NA, et al. Imaging characteristics of indinavir calculi. J Urol 1999;161:1085–7.

⁵¹ Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:296–7.

⁵² Reiter WJ, Schon-Pernerstorfer H, Dorfinger K. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999;161:1082–4.

⁵³ Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001;15:617–20.

⁵⁴ Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med 1999;107:78–84.

⁵⁵ Stenzel MS, Carpenter CC. The management of the clinical complications of antiretroviral therapy. Infect Dis Clin North Am 2000;14:851–78.

⁵⁶ Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001;12:313–9.

⁵⁷ Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001;35:343–51.

⁵⁸ Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21:209–16.

⁵⁹ Vigouroux C, Gharakhanian S, Salhi Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999;25:383–92.

⁶⁰ Bartlett JG, Infectious Disease Society of America, AIDS Clinical Trials Group. New guidelines for management of dyslipidemia from IDSA and the ACTG. Hopkins HIV Rep 2004;16:4–5.

⁶¹ Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003;22:89–99.

⁶² Robinson FP. HIV lipodystrophy syndrome: a primer. J Assoc Nurses AIDS Care 2004;15:15–29.

⁶³ Moyle G, Sutinen J. Managing HIV lipoatrophy. Lancet 2004;363:412–4.

⁶⁴ Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2:812–22.

⁶⁵ Falco V, Crespo M, Ribera E. Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother 2003;4:1321–9.

⁶⁶ Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Inf 2003;79:340–3.

⁶⁷ Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis 2003;36:S96–100.

⁶⁸ Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003;2:812–22.

⁶⁹ Ogedegbe AE, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis 2003;3:329–37.

⁷⁰ Gerard Y, Viget N, Yazdanpanah Y, et al. Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment. Therapie 2003;58:153–8.

⁷¹ Gerberding JL. Clinical practice. Occupational exposure to HIV in health care settings [review]. N Engl J Med 2003;348:826–33.

⁷² Cohen MS. HIV prevention: rethinking the risk of transmission. IAVI Report 2004;8:1–4.

⁷³ Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268–72.

⁷⁴ The organism that causes human Pneumocystis carinii pneumonia has been renamed Pneumocystis jiroveci. See: Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. J Eukaryot Microbiol 1999;46:S89–92. Stringer JR, Cushion MT, Wakefield AE. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol 2001:S184–9. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891–6.

⁷⁵ Chakaya JM, Bii C, Ng’ang’a L, et al. Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. East Afr Med J 2003;80:30–5.

⁷⁶ Malin AS, Gwanzura LK, Klein S, et al. Pneumocystis carinii pneumonia in Zimbabwe. Lancet 1995;346:1258–61.

⁷⁷ Kaplan JE, Hu DJ, Holmes KK, et al. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Am J Trop Med Hyg 1996;55:1–11.

⁷⁸ Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003;36:70–8.

⁷⁹ Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Am J Respir Crit Care Med 1997;155:60.

⁸⁰ Hayes C, Elliot E, Krales E, et al. Food and water safety for persons infected with human immunodeficiency virus. Clin Infect Dis 2003;36:S106–9.

⁸¹ Mwachari C, Meier A, Muyodi J, et al. Chronic diarrhoea in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors and the WHO treatment algorithm. AIDS 2003;17:2124–6.

⁸² Deschamps, M, Fitzgerald, D, Pape, J, et al. HIV infection in Haiti: natural history and disease progression. AIDS 2000;14:2515–21.

⁸³ Brink A, Mahe C, Watera C, et al. Diarrhea, CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. J Infect 2002;45:99–106.

⁸⁴ Cohen J, West A, Bini E. Infectious diarrhea in human immunodeficiency virus. Gastroenterol Clin North Am 2001;30:637–64.

⁸⁵ Mitra A, Hernandez C, Hernandez C, et al. Management of diarrhea in HIV-infected patients. Int J STD AIDS 2001;12:630–9.

⁸⁶ Eddleston M, Pierini S. Oxford handbook of tropical medicine. New York: Oxford University Press, 2002.

⁸⁷ Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford guide to antimicrobial therapy 2006. 36^th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2006.

⁸⁸ Sax P. HIV infection and AIDS. In: Cunha BA, ed. Antibiotic essentials. Royal Oak, MI: Physicians’ Press, 2003.

⁸⁹ Winson S. Management of HIV-associated diarrhea and wasting. J Assoc Nurses AIDS Care 2001;12:S55–62.

⁹⁰ Howling S, Shaw P, Miller R. Acute pulmonary embolism in patients with HIV disease. Sex Transm Infect 1999;75:25–9.

⁹¹ Magula N, Mayosi B. Cardiac involvement in HIV-infected people living in Africa: a review. Cardiovasc J S Afr 2003;14:231–7.

⁹² Diaz P, Wewers M, Pacht E, et al. Respiratory symptoms among HIV-seropositive individuals. Chest 2003;123:1977–82.

⁹³ Wolff A, O’Donnell A. HIV-related pulmonary infections: a review of the recent literature. Curr Opin Pulm Med 2003;9:210–4.

⁹⁴ Freedberg KA, Tosteson AN, Cotton DJ, Goldman L. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis. J Gen Intern Med 1992;7:261–72.

⁹⁵ Drew W, Stempien M, Erlich K. Management of herpesvirus infections. In: Sande MA, Volberding PA, eds. The medical management of AIDS. Philadelphia, PA: W.B. Saunders and Company, 1997.

⁹⁶ Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:370–5.

⁹⁷ Sax P. HIV infection and AIDS. In: Cunha BA, ed. Antibiotic essentials. Royal Oak, MI: Physicians’ Press, 2003.

⁹⁸ Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford guide to antimicrobial therapy 2006. 36^th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2006.

⁹⁹ Sax P. HIV infection and AIDS. In: Cunha BA, ed. Antibiotic essentials. Royal Oak, MI: Physicians’ Press, 2003.

¹⁰⁰ Nola I, Kostovic K, Oremovic L, et al. Candida infections today: how big is the problem? Acta Dermatovenerol Croat 2003;11:171–7.

¹⁰¹ Reichart P. Oral manifestations of HIV infection. Med Microbiol Immunol 2003;192:165–9.

¹⁰² Vazquez J. Invasive esophageal candidiasis: current and developing treatment options. Drugs 2003;63:971–89.

¹⁰³ Cohn SE, Clark RA. Sexually transmitted diseases, HIV, and AIDS in women. Med Clin North Am 2003;87:971–95.

¹⁰⁴ Blignaut E, Messer S, Hollis R, et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and health individuals. Diagn Microbiol Infect Dis 2002;44:169–74.

¹⁰⁵ Weisberg LA. Neurologic abnormalities in human immunodeficiency virus infection. South Med J 2001;94:266–75.

¹⁰⁶ Simpson DM, Berger JR. Neurologic manifestations of HIV infection. Med Clin North Am 1996;80:1363–94.

¹⁰⁷ De Cock KM. Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. WHO AIDS Tech Bull 1989;2:157–8.

¹⁰⁸ Sperber K, Shao L. Neurologic consequences of HIV infection in the era of HAART. AIDS Patient Care STDs 2003;17:509–18.

¹⁰⁹ Weisberg L. Neurologic abnormalities in human immunodeficiency virus infection. South Med J 2001;94:266–75.

¹¹⁰ Civitello L. Neurologic aspects of HIV infection in infants and children: therapeutic approaches and outcome. Curr Neurol Neurosci Rep 2003;3:120–8.

¹¹¹ Antinori A, Giancola M, Alba L, et al. Cardiomyopathy and encephalopathy in AIDS. Ann N Y Acad Sci 2001;946:121–9.

¹¹² Treisman G, Kaplin A. Neurologic and psychiatric complications of antiretroviral agents. AIDS 2002;16:1201–15.

¹¹³ Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769–85.

¹¹⁴ Trujillo JR, Garcia-Ramos G, Novak IS, et al. Neurologic manifestations of AIDS: a comparative study of two populations from Mexico and the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:23–9.

¹¹⁵ Baumgartner J, Rachlin J, Beckstead J, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immune deficiency syndromes. J Neurosurg 1990;73;206–11.

¹¹⁶ Fischer PA, Enzensberger W. Primary and secondary involvement of the CNS in HIV infection. J Neuroimmunol 1998;20:127–31.

¹¹⁷ Kieburtz K, Schiffer RB. Neurologic manifestations of human immunodeficiency virus infections. Neurol Clin 1989;7:447–68.

¹¹⁸ Rachlis AR. Neurologic manifestations of HIV infection. Using imaging studies and antiviral therapy effectively. Postgrad Med 1998;103:147–50,153–61.

¹¹⁹ Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovir 2002;8:158–67.

¹²⁰ Chhin S, Rozycki G, Pugatch D, Harwell JI. Etiology of meningitis in HIV-infected patients in a referral hospital in Phnom Penh, Cambodia. Int J STD AIDS 2004;15:48–50.

¹²¹ Nkoumou MO, Betha G, Kombila M, Clevenbergh P. Bacterial and mycobacterial meningitis in HIV-positive compared with HIV-negative patients in an internal medicine ward in Libreville, Gabon. J Acquir Immune Defic Syndr 2003;32:345–6.

¹²² Forstein M. Psychiatric problems. In: O’Neill JF, Selwyn PA, Schietinger H, eds. A clinical guide to supportive and palliative care for HIV/AIDS. United States Department of Health and Human Resources, Health Resources and Services Administration, 2003:207–52.

¹²³ Goodkin D, Baldewicz TT, Wilkie FL, Tyll MD. Cognitive-motor impairment and disorder in HIV-1 infection. Psychiatr Ann 2001;31:137–44.

¹²⁴ Gartner S. HIV infection and dementia. Science 2000;287:602–4.

¹²⁵ Clay D. Mental health and psychosocial issues in HIV care. Lippincotts Prim Care Pract 2000;4:74–82.

¹²⁶ Rabkin JG. Prevalence of psychiatric disorders in HIV illness. Int Rev Psychiatr 1996;8:157–66.

¹²⁷ Farber E, McDaniel J. Clinical management of psychiatric disorders in patients with HIV disease. Psychiatr Q 2002;73:5–16.

¹²⁸ Farinpour R, Miller E, Satz P, et al. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol 2003;25:654–70.

¹²⁹ Alves R, Kovacs M, Stall R, et al. Psychosocial aspects of HIV infection among women in Brazil. Rev Saude Publica 2002;36:32–9.

¹³⁰ Napolitano L. Approaches to immune reconstitution in HIV infection. Top HIV Med 2003;11:160–3.

¹³¹ Hainaut M, Ducarme M, Schandene L, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003;22:62–9.

¹³² Desimone J, Babinchak T, Kaulback K, et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1 infected individuals. AIDS Patient Care STDs 2003;17:617–22.

¹³³ Goldack N, Allen S, Lipman M. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003;79:337–8.

¹³⁴ Jenny-Avital E, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002;35:e128–33.

¹³⁵ Stone S, Price P, Tay-Kearney M, et al. Cytomegalovirus retinitis immune restoration disease occurs during highly active antiretroviral therapy induced restoration of CMV-specific immune response within a predominant Th2 cytokine environment. J Infect Dis 2002;185:1813–7.

¹³⁶ Crothers K, Huang L. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy. HIV Med 2003;4:346–9.

¹³⁷ Robertson P, Scadden D. Immune reconstitution in HIV infection and its relationship to cancer. Hematol Oncol Clin North Am 2003;17:703–16.

¹³⁸ Shelburne SA, Hamil RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67–79.

¹³⁹ Liechty CA, Bangsberg DR. Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS 2003;17:1383–7.

¹⁴⁰ Mukherjee JS, Farmer PE, Niyizonkiza D, et al. Tackling HIV in resource poor countries. BMJ 2003; 237:1104–6.

¹⁴¹ Behforouz H, Farmer P, Mukherjee JS. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 2004;38:S429–36.

¹⁴² Kuritzkes DR. Preventing and managing resistance in the clinical setting. J Acquir Immume Defic Syndr 2003;34:S103–10.

¹⁴³ Farmer P. AIDS and accusation: Haiti and the geography of blame. Berkeley, CA: University of California Press, 1992.

¹⁴⁴ Farmer P. Infections and Inequalities: The Modern Plagues. Berkeley, CA: University of California Press, 1999.

¹⁴⁵ Sauve N, Dzokoto A, Opare B, et al. The price of development: HIV infection in a semiurban community of Ghana. J Acquir Immune Defic Syndr 2002;29:402–8.

¹⁴⁶ Penner J, Meier AS, Mwachari C, et al. Risk factors for pneumonia in urban-dwelling HIV-infected women: a case-control study in Nairobi, Kenya. J Acquir Immune Defic Syndr 2003;32:223–8.

¹⁴⁷ Davies PD. The world-wide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 2003;35:235–43.

¹⁴⁸ Killewo J. Poverty, TB, and HIV infection: a vicious cycle. J Health Popul Nutr 2002;20:281–4.

¹⁴⁹ Grange J, Story A, Zumla A. Tuberculosis in disadvantaged groups. Curr Opin Pulm Med 2001;7:160–4.

¹⁵⁰ Henry F. Nutrition in AIDS management: An opportunity being lost. West Indian Med J 2003;52:89–90.

¹⁵¹ Sherlekar S, Udipi S. Role of nutrition in the management of HIV infection/AIDS. J Indian Med Assoc 2002;100:385–90.

¹⁵² Charlton K, Rose D. Nutrition among older adults in Africa: the situation at the beginning of the millennium. J Nutr 2001;131:S2424–8.

¹⁵³ Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Medicine 2006;7:323–30.

¹⁵⁴ Kotler D. Nutritional alterations associated with HIV infection. J Acquir Immune Defic Syndr 2000;25:S81–7.

¹⁵⁵ Wanke C, Silva M, Ganda A, et al. Role of AIDS-defining conditions in HIV-associated wasting. Clin Infect Dis 2003;37:S81–4.

¹⁵⁶ Hayes C, Elliot E, Krales E, Downer G. Food and water safety for persons infected with HIV. Clin Infect Dis 2003;36:S106–9.

¹⁵⁷ Leclerc H, Schwartzbrod L, Dei-Cas E. Microbial agents associated with waterborne diseases. Crit Rev Microbiol 2002;28:371–409.

¹⁵⁸ Hunter P, Nichols G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 2002;15:145–54.